Short Squeeze Round 2: GME, AMC, EXPR, OTRK, KOSS, LIVE

Meme stocks are back in play with round 2 of the short squeeze. GME breached $200 for the first time since February 1. All the other major meme stocks rose, and we are on the watch for more short squeeze potential. Here's a chart of the hottest meme stocks and short squeezes:


Data was grabbed from Yahoo Finance. We see that short interest as a percentage of the float remains high for GME at 60.35%, highlighting its continued potential to squeeze. Next highest on the list is OTRK with 30.21%. It's actually much higher than other meme stocks that moved today like AMC and EXPR. WSB is currently restricting posts on OTRK due to the $1 billion market cap rule, but other stocks with smaller market caps like EXPR get mentioned all the time. We think that the mods behind the group are trying to downplay OTRK so it doesn't run so much and they can load up cheaply before they let OTRK turn into a meme stock like the others. 

LIVE remains a dark horse play. The short interest is low, but it doesn't really need short interest because of its extremely small float of only 1.27 million shares. KOSS has always had a low short interest but that didn't stop the stock from running to over $100 from $10. LIVE's float is less than half of KOSS. Also LIVE is the only one in the group that has earnings and a P/E ratio. Most P/E ratios are around 20 so LIVE being at only 5 makes the stock four times undervalued. We think it can reach $100 to come more in line with average P/E ratio numbers. 


Comments

  1. UnknownMarch 8, 2021 at 9:09 PM

    $thmo and $ntn to the moon!!!!!

    ReplyDelete
  2. skipmannMarch 9, 2021 at 4:21 PM

    You need to add $PPBT to this list...NT219 curing cancer in humans, Morgan Stanley purchased %5 of the company earlier this month, low float, Sabby's vulture fund shorting it to hell - would love to see this go into a gamma squeeze and obliterate the shorts. Who would short a potential cancer cure?

    ReplyDelete
  3. UnknownMarch 10, 2021 at 8:56 AM

    NVIV to the moon? really? ok

    ReplyDelete
    Replies
    1. knightflyerJune 22, 2021 at 1:59 PM

      NVIV is at .72. Not exactly the moon but digest this: NVIV has a phase 3 fda trial now in the home stretch and it has cash on hand adequate to run to mid 2023. So what?
      The trial is for a synthetic spinal cord implant that more than doubles chances of completely paralyzed patients to "convert". There is no competition. An earlier pre-pivotal fda trial showed positive results on humans not rats, rabbits, mice or dogs. Current trial is for 20 patients and so far there are 14 recruits. Sounds like a decent gamble at .72.

      Delete
  4. RonsterMonsterAugust 31, 2021 at 12:16 PM

    LIVE has never been anywhere near $100. Highest historic is $75, but very respectable.

    ReplyDelete

Post a Comment

Popular posts from this blog

The Two Best Biotech Short Squeeze Candidates And The Next Carvana

Image
With the market having recovered most of its recent drop to be near all-time highs once again, shorts have been destroyed and are in a desperate spot. Heavily shorted stocks like B. Riley Financial, Inc. (RILY), Globe Life Inc. (GL) and Carvana Co. (CVNA) have been on absolute tears. We have written about CVNA before , as well as the impact of CVNA's move on Root , Inc. (ROOT). When a stock is squeezing like CVNA, a related stock like ROOT will follow suit. Shorts are often shorting multiple related stocks. Most don't even hide it with Kerrisdale openly bragging about its poor track record. GL was another one that was attacked by shorts which we talked about as a gamma squeeze candidate that has worked out very well over the past three weeks.  In this market of short squeezes, we have identified two excellent biotech short squeeze candidates, ImmunityBio, Inc. (IBRX) and Soleno Therapeutics, Inc. (SLNO). IBRX is starting up the production and sale of its cancer drug ANKT...
Read more

The Next NVDA-Backed Runner and New Asian IPO Squeeze Play

Image
We have seen stocks like Super Micro Computer, Inc. (SMCI) and SoundHound AI, Inc. (SOUN) have incredible squeeze runs thanks to their connection to NVIDIA Corporation (NVDA). We think the next one will be Spire Global, Inc. (SPIR), which popped a week ago after it announced a collaboration with NVDA to enhance AI-driven weather prediction. A few day later it dropped on the announcement of a financing at $14, with the potential to raise $61 million if warrants at $14.50 are exercised. We think there is a good chance that NVDA got in on this financing, as it tends to invest in the companies it does these deals with when spreading AI across different sectors. One such recent example was with Recursion Pharmaceuticals, Inc. (RXRX) for AI in drug development.  It looks like SPIR didn't really need this financing as it has enough cash and looks like it will be cash flow and net income positive in 2024. This financing was of a strategic nature, not something led by broker...
Read more

Forget about CVNA, PLCE is the Next Major Short Squeeze Play

Image
 Back in June, we called out Kerrisdale Capital and its short on Carvana Co. (CVNA) in our piece " Carvana: The Gamma Squeeze is Real, Time to Bankrupt Kerrisdale ". Kerrisdale has a history of calling one bad short after another, creating a squeeze on all of its positions as the firm and its associates face liquidity crises. Kerrisdale is once again on a cold streak as its short on Altimmune, Inc. (ALT) simultaneously blew up just as CVNA headed from $70 to $80 this week.  However, we think CVNA is done for now. Recall that in June after the initial spike to nearly $30, the stock pulled back to $20 before hitting $40 in the next month. People who are riding weekly call options aren't likely to cash in. CVNA looks headed to the mid to low $60's to close the gap that currently exists in the $62 to $66 area before resuming any further rise. Kerrisdale created an artificial short squeeze with its report, but now that both ALT and CVNA have come down from their weekly hig...
Read more